Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Newron Pharmaceuticals SpA    NWRN   IT0004147952

Delayed Quote. Delayed  - 09/22 05:31:08 pm
15.5 CHF   -0.64%
09/14 NEWRON PHARMACE : Reports Half-Year 2017 Results
09/14 Newron reports half-year 2017 results
09/14 NEWRON PHARMACE : reports half-year 2017 results
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
09/18/2017 09/19/2017 09/20/2017 09/21/2017 09/22/2017 Date
16.6(c) 16.35(c) 16.2(c) 15.6(c) 15.5(c) Last
89 330 68 324 22 696 145 646 96 994 Volume
-3.21% -1.51% -0.92% -3.70% -0.64% Change
More quotes
Financials (€)
Sales 2017 12,1 M
EBIT 2017 -11,7 M
Net income 2017 -16,4 M
Finance 2017 54,0 M
Yield 2017 -
Sales 2018 10,5 M
EBIT 2018 -28,4 M
Net income 2018 -30,0 M
Finance 2018 25,0 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 13,0x
EV / Sales2018 17,7x
Capitalization 212 M
More Financials
Company
Newron Pharmaceuticals SpA is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the Central Nervous System (CNS) and pain.The focus of its treatments includes patients with Parkinson's disease, Rett Syndrome, Amyotrophic Lateral Sclerosis,... 
More about the company
Surperformance© ratings of Newron Pharmaceuticals SpA
Trading Rating : Investor Rating :
More Ratings
Latest news on NEWRON PHARMACEUTICALS SPA
09/14 NEWRON PHARMACEUTICALS : Reports Half-Year 2017 Results
09/14 Newron reports half-year 2017 results
09/14 NEWRON PHARMACEUTICALS : reports half-year 2017 results
09/11NEWRON PHARMACEUTICALS SPA : half-yearly earnings release
08/03 NEWRON PHARMACEUTICALS : LavoieHealthScience Selected as an MM&M Award Finalist ..
07/11 XADAGO® (SAFINAMIDE) NOW AVAILABLE IN THE U.S. FOR PARKINSON’S DISEASE ..
07/11 NEWRON PHARMACEUTICALS : XADAGO® (Safinamide) Now Available in the U.S. for Park..
05/30 NEWRON PHARMACEUTICALS : to Present at the Jefferies 2017 Healthcare Conference ..
05/18 NEWRON PHARMACEUTICALS : Announces a Poster Presentation at the International So..
05/17 Newron Pharmaceuticals Announces Expansion of STARS Study to Include Patients..
More news
Sector news : Bio Therapeutic Drugs
09/20DJSANOFI : Alnylam Report Positive Patisiran Phase III Trial, First-Ever for RNAi ..
09/15 Drug industry on tenterhooks as Maryland price-gouging law nears
09/07 New AstraZeneca, Amgen drug looks strong rival in severe asthma
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag -- Update
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag
More sector news : Bio Therapeutic Drugs
Latest Tweets
09/14Newron Pharmaceuticals SPA reports 1H results  
07/11Newron Pharmaceuticals : XADAGO® (Safinamide) Now Available in the U.S. for P.. 
05/30Newron Pharmaceuticals : to Present at the Jefferies 2017 Healthcare Conferen.. 
05/17Newron Pharmaceuticals : Announces Expansion of STARS Study to Include Patien.. 
05/12Newron Pharmaceuticals : Receives EUR11.3m Milestone Payments for US Approval.. 
More tweets
Qtime:6
News from SeekingAlpha
09/14 Newron Pharmaceuticals SPA reports 1H results
03/02 Newron Pharmaceuticals SPA reports FY results
2016 FDA accepts for review Newron's resubmitted NDA for Xadago; action date March..
2016 Newron Pharmaceuticals SPA reports 1H results
2015 TOP 2 TRADE ALERT IDEAS SEPTEMBER 30 : Esperion Sell-Off, Clovis Milestone, Wind..
Chart NEWRON PHARMACEUTICALS SPA
Duration : Period :
Newron Pharmaceuticals SpA Technical Analysis Chart | NWRN | IT0004147952 | 4-Traders
Technical analysis trends NEWRON PHARMACEUTICALS SPA
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 31,4 €
Spread / Average Target 135%
EPS Revisions
Managers
NameTitle
Stefan Weber Chief Executive Officer, Director & IR Contact
Ulrich Köstlin Non-Executive Chairman
Roberto Galli Vice President-Finance
Ravi Anand Chief Medical Officer
Patrick J. Langlois Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NEWRON PHARMACEUTICALS SPA-19.60%253
AMGEN28.70%136 186
CELGENE CORPORATION24.61%112 486
GILEAD SCIENCES15.40%107 896
REGENERON PHARMACEUTICALS19.36%46 445
VERTEX PHARMACEUTICALS107.30%38 337